Rare genetic variants involved in multisystem inflammatory syndrome in children: a multicenter Brazilian cohort study

Introduction Despite the existing data on the Multisystem Inflammatory Syndrome in Children (MIS-C), the factors that determine these patients evolution remain elusive. Answers may lie, at least in part, in genetics. It is currently under investigation that MIS-C patients may have an underlying innate error of immunity (IEI), whether of monogenic, digenic, or even oligogenic origin. Methods To further investigate this hypothesis, 30 patients with MIS-C were submitted to whole exome sequencing. Results Analyses of genes associated with MIS-C, MIS-A, severe covid-19, and Kawasaki disease identified twenty-nine patients with rare potentially damaging variants (50 variants were identified in 38 different genes), including those previously described in IFNA21 and IFIH1 genes, new variants in genes previously described in MIS-C patients (KMT2D, CFB, and PRF1), and variants in genes newly associated to MIS-C such as APOL1, TNFRSF13B, and G6PD. In addition, gene ontology enrichment pointed to the involvement of thirteen major pathways, including complement system, hematopoiesis, immune system development, and type II interferon signaling, that were not yet reported in MIS-C. Discussion These data strongly indicate that different gene families may favor MIS- C development. Larger cohort studies with healthy controls and other omics approaches, such as proteomics and RNAseq, will be precious to better understanding the disease dynamics.

[1]  J. Casanova,et al.  Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children , 2022, Science.

[2]  Rangel C. Souza,et al.  Host genetic susceptibility underlying SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Brazilian Children , 2022, Molecular medicine.

[3]  A. La Cava,et al.  MIS-C: A COVID-19-as sociated condition between hypoimmunity and hyperimmunity , 2022, Frontiers in Immunology.

[4]  J. Casanova,et al.  Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19 , 2022, Journal of Allergy and Clinical Immunology.

[5]  D. Zafeiriou,et al.  Targeted Genotyping of MIS-C Patients Reveals a Potential Alternative Pathway Mediated Complement Dysregulation during COVID-19 Infection , 2022, Current issues in molecular biology.

[6]  R. Almaghrabi,et al.  Multisystemic Inflammatory Syndrome in Neonates: A Systematic Review , 2022, Neonatology.

[7]  A. Alsheikh-Ali,et al.  Genetic and Clinical Characteristics of Patients in the Middle East With Multisystem Inflammatory Syndrome in Children , 2022, JAMA network open.

[8]  R. Cron,et al.  Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children , 2022, Biology.

[9]  S. Prahalad,et al.  Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH) , 2022, Journal of Allergy and Clinical Immunology.

[10]  M. Askenazi,et al.  Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 , 2022, Nature Medicine.

[11]  H. Takada,et al.  Time course of peripheral immunophenotypes of multisystem inflammatory syndrome in children , 2022, Clinical Immunology.

[12]  J. Casanova,et al.  Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome , 2022, Journal of Clinical Immunology.

[13]  B. Lambrecht,et al.  The state of complement in COVID-19 , 2021, Nature Reviews Immunology.

[14]  P. Kearns,et al.  The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery , 2021, iScience.

[15]  J. Cesbron,et al.  Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality , 2021, Frontiers in Immunology.

[16]  Lina Lim,et al.  Multisystem inflammatory syndrome in children (MIS-C) occurring in temporal proximity between siblings , 2021, BMJ Case Reports.

[17]  P. Patel,et al.  Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults , 2021, JAMA network open.

[18]  M. Storgaard,et al.  Host Genetics and Antiviral Immune Responses in Adult Patients With Multisystem Inflammatory Syndrome , 2021, Frontiers in Immunology.

[19]  R. Nussbaum,et al.  X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 , 2021, Science immunology.

[20]  J. Heeney,et al.  Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins , 2021, Frontiers in Immunology.

[21]  David A. Williams,et al.  Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C) , 2021, Journal of Allergy and Clinical Immunology.

[22]  U. Ramenghi,et al.  COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases , 2021, International journal of molecular sciences.

[23]  Mark S. Anderson,et al.  SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease? , 2021, The Journal of experimental medicine.

[24]  D. Hafler,et al.  Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children , 2021, Immunity.

[25]  Theodore S. Kouo,et al.  SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children (MIS-C). , 2021, Journal of Clinical Investigation.

[26]  A. Ramaswamy,et al.  Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Ramaswamy et al. 2021 Supplementary Tables , 2021 .

[27]  M. Tobin-D'Angelo,et al.  Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic. , 2021, JAMA pediatrics.

[28]  J. Schuurs-Hoeijmakers,et al.  Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19 , 2021, Frontiers in Immunology.

[29]  M. H. Cheng,et al.  HLA class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children. , 2021, The Journal of clinical investigation.

[30]  X. Gong,et al.  Structural basis of substrate recognition and translocation by human ABCA4 , 2021, Nature Communications.

[31]  J. Franco,et al.  The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee , 2021, Journal of Clinical Immunology.

[32]  J. Lipton,et al.  Effect of COVID‐19 on anakinra‐induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis , 2021, Pediatric blood & cancer.

[33]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[34]  M. H. Cheng,et al.  Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation , 2020, Proceedings of the National Academy of Sciences.

[35]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[36]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[37]  S. Tibby,et al.  A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process , 2020, The Lancet Child & Adolescent Health.

[38]  Douglas R. McDonald,et al.  Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1 , 2020, Journal of Allergy and Clinical Immunology.

[39]  K. Reilly,et al.  COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[40]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[41]  L. Álvarez-Vallina,et al.  Perforin gene variant A91V in young patients with severe COVID-19. , 2020, Haematologica.

[42]  M. Ratajczak,et al.  SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45− Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome , 2020, Stem Cell Reviews and Reports.

[43]  P. Palma,et al.  The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 , 2020, Cell.

[44]  David R. Holtgrave,et al.  Multisystem Inflammatory Syndrome in Children in New York State , 2020, The New England journal of medicine.

[45]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[46]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[47]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[48]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[49]  K. Brengel-Pesce,et al.  Type I IFN immunoprofiling in COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.

[50]  R. Cron,et al.  The genetics of macrophage activation syndrome , 2020, Genes & Immunity.

[51]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification , 2020, Journal of Clinical Immunology.

[52]  Jesper Eisfeldt,et al.  Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants , 2018, bioRxiv.

[53]  C. Jin,et al.  Clinical and next-generation sequencing findings in a Chinese family exhibiting severe familial exudative vitreoretinopathy , 2017, International journal of molecular medicine.

[54]  R. Tothill,et al.  Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals , 2015, Immunology and cell biology.

[55]  Roland Eils,et al.  circlize implements and enhances circular visualization in R , 2014, Bioinform..

[56]  Fuu-Jen Tsai,et al.  Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis , 2012, Nature Genetics.

[57]  Yusuke Nakamura,et al.  A genome-wide association study identifies three new risk loci for Kawasaki disease , 2012, Nature Genetics.

[58]  Fuu-Jen Tsai,et al.  Identification of Novel Susceptibility Loci for Kawasaki Disease in a Han Chinese Population by a Genome-Wide Association Study , 2011, PloS one.

[59]  Anbupalam Thalamuthu,et al.  A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki Disease , 2009, PLoS genetics.

[60]  J. Trapani,et al.  Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. , 2007, Blood.

[61]  H Yanagawa,et al.  Kawasaki disease in parents and children , 2003, Acta paediatrica.

[62]  M. Kool,et al.  Mutations in ABCC6 cause pseudoxanthoma elasticum , 2000, Nature Genetics.

[63]  H. Yanagawa,et al.  Kawasaki disease in families. , 1989, Pediatrics.

[64]  Multisystem In fl ammatory Syndrome in Children , 2022 .